{"id":68693,"date":"2026-06-29T18:56:06","date_gmt":"2026-06-29T16:56:06","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/06\/29\/high-dimensional-single-cell-mass-cytometry-analysis-of-il-4-treated-human-macrophages-reveals-heterogeneity-and-a-cd206high-anticolitic-subsetblanca-e-callejas-on-29-de-june-de-2026-at-10\/"},"modified":"2026-06-29T18:56:06","modified_gmt":"2026-06-29T16:56:06","slug":"high-dimensional-single-cell-mass-cytometry-analysis-of-il-4-treated-human-macrophages-reveals-heterogeneity-and-a-cd206high-anticolitic-subsetblanca-e-callejas-on-29-de-june-de-2026-at-10","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/06\/29\/high-dimensional-single-cell-mass-cytometry-analysis-of-il-4-treated-human-macrophages-reveals-heterogeneity-and-a-cd206high-anticolitic-subsetblanca-e-callejas-on-29-de-june-de-2026-at-10\/","title":{"rendered":"High-dimensional single-cell mass cytometry analysis of IL-4 treated human macrophages reveals heterogeneity and a CD206high anticolitic subset\u200bBlanca E Callejas on 29 de June de 2026 at 10:00"},"content":{"rendered":"
\n

J Leukoc Biol<\/b>. 2026 Jun 8;118(6):qiag075. doi: 10.1093\/jleuko\/qiag075.<\/p>\n

ABSTRACT<\/b><\/p>\n

Autologous cell therapy is a patient-embraced approach to inflammatory disease. Murine models demonstrate that alternatively activated (or regulatory) macrophages can reduce the severity of disease, and human macrophages (M0) educated with interleukin-4 (M(IL4)) limit murine colitis. M0 and M(IL4) from healthy donors and individuals with Crohn’s disease (active or remission) were assessed by qPCR, characterized by a time-of-flight mass cytometry (CyTOF) comparison of 16 myeloid marker molecules expression, and subtypes of M(IL4)s tested in the murine dinitrobenzene sulfonic acid (DNBS) model of colitis and in vitro co-culture with T cells. Most macrophage preparations responded to IL-4 by increasing CD206, CCL18 and RAMP1 mRNA expression and produced mediators that promoted epithelial repair in a wound assay with the human CaCo2 epithelial line. Single-cell clustering by FlowSOM defined 8 distinct subpopulations (meta-clusters) of macrophages, the proportions of which were unaffected by biological sex, age or cryopreservation: meta-cluster 4 (CD206highPD-L1highHLA-DRhigh) represented 20 to 40% of M0s, with a higher proportion in controls compared with active Crohn’s disease. IL-4 treatment significantly expanded meta-cluster 4 in all M0s. Transfer of M(IL4)-CD206high (ie, predominantly meta-cluster 4) into rag1-\/- mice significantly reduced DNBS-induced colitis, and to a greater extent than M(IL4)-CD206low from the same individual. IL-10 production was increased in M(IL4)-CD206high-T-cell co-cultures. Having confirmed the prohealing effect of the human M(IL4), the predominant meta-cluster M(IL4)-CD206high was found to have superior anticolitic effect. Reduced numbers of M0-CD206high and M(IL4)-CD206high cells in some individuals with Crohn’s disease suggest that their absence may contribute to more severe inflammation or reduced healing capacity.<\/p>\n

PMID:42367148<\/a> | DOI:10.1093\/jleuko\/qiag075<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

J Leukoc Biol. 2026 Jun 8;118(6):qiag075. doi: 10.1093\/jleuko\/qiag075. ABSTRACT Autologous cell therapy is a patient-embraced approach to inflammatory disease. Murine models demonstrate that alternatively activated (or regulatory) macrophages can reduce the severity of disease, and human macrophages (M0) educated with interleukin-4 (M(IL4)) limit murine colitis. M0 and M(IL4) from healthy donors and individuals with Crohn’s … Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[86,42],"tags":[],"class_list":["post-68693","post","type-post","status-publish","format-standard","hentry","category-journal-of-leukocyte-biology","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/68693","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=68693"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/68693\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=68693"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=68693"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=68693"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}